Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma

NCT05464433 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Extranodal Natural Killer T Cell Lymphoma

Interventions

DRUG: Tislelizumab combined with Liposomal mitoxantrone hydrochloride
DRUG: Maintenance of tislelizumab

Sponsor

Sun Yat-sen University